Cover Image
市場調查報告書

Frontier Pharma:氣喘治療 - 細胞激素、激酶作為標的小分子、mAb (單株抗體)提高開發平台的多樣性,First-in-Class的革新的特色

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

出版商 GBI Research 商品編碼 399712
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
Frontier Pharma:氣喘治療 - 細胞激素、激酶作為標的小分子、mAb (單株抗體)提高開發平台的多樣性,First-in-Class的革新的特色 Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation
出版日期: 2016年11月01日 內容資訊: 英文 61 Pages
簡介

本報告提供氣喘治療藥市場相關調查分析,革新案例,臨床、商業性情形,開發中產品的評估,計劃評估,最近的交易等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 氣喘市場上革新案例

  • 生技藥品的機會擴大
  • 分子標的多樣化
  • 創新的First-in-Class產品 (劃時代的醫藥品)的開發現在也富有魅力
  • 臨床、商業環境的變化,成為比把利基的患者族群、症狀作為目標的產品而言有利的東西
  • 持續性的革新
  • GBI調查報告的指導

第4章 臨床、商業性情形

  • 疾病概要
  • 流行病學
  • 病因
  • 病理學
  • 疾病的症狀
  • 診斷
  • 治療
  • 上市產品概要
  • 氣喘市場上目前未滿足需求

第5章 開發中產品革新的評估

  • 氣喘治療藥開發平台:各分子類型,開發階段,分子標的
  • 氣喘治療藥市場與開發平台的計劃比較分佈:各治療標的
  • 以新分子標的為目標的First-in-Class開發平台的計劃

第6章 信號 (信號傳達) 網路及革新的調整

  • 氣喘的信號傳達網路的複雜
  • First-in-Class標的矩陣的評估

第7章 First-in-Class標的評估

第8章 交易與策略性整合

  • 產業整體First-in-Class交易
  • 氣喘的契約形勢
  • 許可證交易
  • 共同開發交易
  • 不參與許可證/共同開發交易的First-in-Class計劃

第9章 附錄

圖表

目錄
Product Code: GBIHC423MR

Asthma is a chronic condition affecting the respiratory system, with disease occurrence linked to both genetic and environmental factors. It has significant global incidence and there is currently no cure. Pharmacotherapeutic intervention aims to provide patients with an increased level of disease control and reduce the severity of symptoms, and a number of inhalational therapeutic options are available.

While the asthma market is dominated almost exclusively by small molecules, which account for 99.6% of available products, the asthma pipeline consists of 13% general biologics and 12% monoclonal Antibodies (mAb). There are 173 small molecules, equating to 65%. The rise in mAb development is possibly due to the success of Xolair (omalizumab), one of the few currently marketed mAb asthma therapeutics, which reached blockbuster status in 2014. Xolair is a recombinant humanized anti-IgE, and was the first humanized therapeutic mAb to be indicated for asthma.

Over the past decade, the pharmaceutical industry has witnessed a profound change in the technological, clinical and commercial landscape across several therapeutic areas and indications. These changes include a remarkable transition towards biologic products in R&D, on an unprecedented scale. This has been facilitated by significant advances in recombinant DNA technologies, which accelerated the capabilities in the design of biologic therapeutics and substantially improved the yields in the manufacturing processes for biologics, improving productivity and profitability. As a result of these developments, the number and diversity of molecule types in developmental pipelines have increased substantially, and are expected to continue to grow in the years to come, particularly mAbs, proteins, peptides and vaccines.

The prevalence of asthma in the US increased from 7.3% in 2001 to 8.4% in 2010 (CDC, 2012). Data derived from the same study also confirmed the prevalence of asthma to be higher among children than adults, and higher among multiple-race, black, and American Indian or Alaska Native people than white people, for the 2008-2010 period.

The report "Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation" provides the following:

  • Analysis of innovation in the asthma market in the context of the overall pipeline and current market landscape - also includes analysis of the deals landscape surrounding first-in-class products in asthma, and highlights opportunities for in-licensing.
  • A brief introduction to asthma, including symptoms, pathophysiology, and an overview of pharmacotherapy.
  • The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
  • Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
  • Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
  • Assessment of the licensing and co-development deal landscape for asthma therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. Biologics and mAbs Growing in Prominence in Asthma Treatment
  • 2.2. Market Landscape to Grow in Diversity over Coming Years
  • 2.3. Cytokine and Kinase Targeted Small Molecules and mAbs Dominate First-in-Class Innovation
  • 2.4. Deals Landscape Offers Significant Investment Opportunities for First-in-Class Products

3. The Case for Innovation in the Asthma Market

  • 3.1. Growing Number of Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Product Developments Remain Attractive
  • 3.4. Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications
  • 3.5. Sustained Innovation
  • 3.6. GBI Research Report Guidance

4. Clinical and Commercial Landscape

  • 4.1. Disease Overview
  • 4.2. Epidemiology
  • 4.3. Etiology
  • 4.4. Pathophysiology
  • 4.5. Disease Symptoms
  • 4.6. Diagnosis
    • 4.6.1. Disease Prgnosis
    • 4.6.2. Assessment of Disease Severity
  • 4.7. Treatment
    • 4.7.1. Quick-Relief Medication
    • 4.7.2. ICSs for the Maintenance Treatment of Asthma
    • 4.7.3. ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma
    • 4.7.4. Add-on Therapies to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma
    • 4.7.5. Treatment Algorithm
  • 4.8. Overview of Marketed Products
  • 4.9. Current Unmet Need in the Asthma Market

5. Assessment of Pipeline Product Innovation

  • 5.1. Asthma Pipeline by Molecule Type, Stage of Development and Molecular Target
  • 5.2. Comparative Distribution of Programs between the Asthma Market and Pipeline by Molecular Target
  • 5.3. First-in-Class Pipeline Programs Targeting Novel Molecular Targets

6. Signaling Network and Innovation Alignment

  • 6.1. Complexity of Signaling Networks in Asthma
  • 6.2. First-in-Class Matrix Assessment

7. First-in-Class Target Evaluation

  • 7.1. Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1
    • 7.1.1. Overview of Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1
  • 7.2. Pipeline Programs Targeting CXC Chemokine Receptors
    • 7.2.1. Overview of Pipeline Programs Targeting CXC Chemokine Receptors
  • 7.3. Pipeline Programs Targeting Spleen Tyrosine Kinase
    • 7.3.1. Overview of Pipeline Programs Targeting Spleen Tyrosine Kinase
  • 7.4. Pipeline Programs Targeting Compliment Component 5a Receptor 1
    • 7.4.1. Overview of Pipeline Programs Targeting Compliment Component 5a Receptor 1
  • 7.5. Pipeline Programs Targeting Interleukin-33
    • 7.5.1. Overview of Pipeline Programs Targeting Interleukin-33
  • 7.6. Pipeline Programs Targeting CC Chemokine Receptor Type 3
    • 7.6.1. Overview of Pipeline Programs Targeting CC Chemokine Receptor Type 3
  • 7.7. Pipeline Programs Targeting Antigen Presenting Glycoprotein CD1d
    • 7.7.1. Overview of Pipeline Programs Targeting Antigen Presenting Glycoprotein CD1d
  • 7.8. Pipeline Programs Targeting Interleukin 4 Receptor Subunit Alpha
    • 7.8.1. Overview of Pipeline Programs Targeting Interleukin 4 Receptor Subunit Alpha
  • 7.9. Conclusion

8. Deals and Strategic Consolidations

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Asthma Deals Landscape
  • 8.3. Licensing Deals
    • 8.3.1. Molecule Type
    • 8.3.2. Molecular Target
  • 8.4. Co-development Deals
    • 8.4.1. Molecule Type
    • 8.4.2. Molecular Target
  • 8.5. Pipeline Products without Prior Licensing or Co-Development Deal Involvement

9. Appendix

  • 9.1. References
  • 9.2. Abbreviations
  • 9.3. Primary Research
  • 9.4. Contact Us
  • 9.5. Disclaimer

List of Tables

  • Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children Aged 0-4
  • Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children Aged 5-11
  • Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths ≥12 Years of Age and Adults
  • Table 4: Asthma Therapeutics Market, Global, Management of Chronic Asthma
  • Table 5: Asthma Therapeutics Market, Global, Management of Chronic Asthma
  • Table 6: Asthma Therapeutics Market, Global, Management of Acute Asthma
  • Table 7: Asthma Therapeutics Market, Global, Data for Calcium Release Activated Calcium Channel Protein 1 as a Molecular Target
  • Table 8: Asthma Therapeutics Market, Global, Data for CXC Chemokine Receptors as Molecular Targets, 2016
  • Table 9: Asthma Therapeutics Market, Global, Data for Spleen Tyrosine Kinase as a Molecular Target, 2016
  • Table 10:Asthma Therapeutics Market, Global, Data for Compliment Component 5a Receptor 1 as a Molecular Target, 2016
  • Table 11: Asthma Therapeutics Market, Global, Data for Interleukin-33 as a Molecular Target, 2016
  • Table 12:Asthma Therapeutics Market, Global, Data for CC Chemokine Receptor Type-3 as a Molecular Target, 2016
  • Table 13:Asthma Therapeutics Market, Global, Data for Antigen Presenting Glycoprotein CD1d as a Molecular Target, 2016
  • Table 14: Asthma Therapeutics Market, Global, Data for Interleukin 4 Receptor Subunit Alpha as a Molecular Target, 2016

List of Figures

  • Figure 1: Overall Pharmaceutical Industry, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987-2014
  • Figure 2: Overall Pharmaceutical Industry, First-in-Class and Non-First-in-Class Products, Sales Performance After Marketing Approval, 2006-2013 ($m)
  • Figure 3: Asthma Therapeutics Market, Global, Marketed Product Overview, 2016
  • Figure 4: Pharmaceutical Market, Global, Developmental Pipeline Overview, 2016
  • Figure 5: Asthma Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type, 2016
  • Figure 6: Asthma Therapeutics Market, Global, Pipeline by Molecular Target and Cytokine/Cytokine Receptor Subcategory, 2016
  • Figure 7: Asthma Therapeutics Market, Global, Pipeline by Molecular Target Subcategories, 2016
  • Figure 8: Asthma Therapeutics Market, Global, Molecular Target Category Comparison, Pipeline and Marketed Products, 2016
  • Figure 9: Asthma Therapeutics Market, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2016
  • Figure 10: Asthma Therapeutics Market, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2016
  • Figure 11: Asthma Therapeutics Market, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%), 2016
  • Figure 12: Asthma Therapeutics Market, Global, First-in-Class Molecular Targets in Pipeline Development, 2016
  • Figure 13: Asthma Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix, 2016
  • Figure 14: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1, 2016
  • Figure 15: Asthma Therapeutics Market, Global, Pipeline Programs Targeting CXC Chemokine Receptors, 2016
  • Figure 16: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Spleen Tyrosine Kinase, 2016
  • Figure 17: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Compliment Component 5a Receptor 1, 2016
  • Figure 18: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Interleukin-33, 2016
  • Figure 19: Asthma Therapeutics Market, Global, Pipeline Programs Targeting CC Chemokine Receptor Type-3, 2016
  • Figure 20: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Antigen Presenting Glycoprotein CD1d, 2016
  • Figure 21: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Interleukin 4 Receptor Subunit Alpha, 2016
  • Figure 22: Pharmaceutical Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014
  • Figure 23: Pharmaceutical Market, Global, Industry Licensing Deal Values by Stage of Development, 2006-2014
  • Figure 24: Asthma Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
  • Figure 25: Asthma Therapeutics Market, Global, Licensing Deals by Stage of Development, 2006-2016
  • Figure 26: Asthma Therapeutics Market, Global, Licensing Deals by Molecule Type, 2006-2016
  • Figure 27: Asthma Therapeutics Market, Global, Licensing Deals by Molecular Target, 2006-2016
  • Figure 28: Asthma Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
  • Figure 29: Asthma Therapeutics Market, Global, Co-Development Deals by Region and Value, 2006-2016
  • Figure 30: Asthma Therapeutics Market, Global, Co-Development Deals by Stage of Development, 2006-2016
  • Figure 31: Asthma Therapeutics Market, Global, Co-Development Deals by Molecule Type, 2006-2016
  • Figure 32: Asthma Therapeutics Market, Global, Co-Development Deals by Molecular Target, 2006-2016
  • Figure 33: Asthma Therapeutics Market, Global, Co-Development Deals Valued Above $100m, 2006-2016
  • Figure 34: Asthma Therapeutics Market, Global, First-in-class Programs in Active Development Involved in Previous Deals, 2016
  • Figure 35: Asthma Therapeutics Market, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2016
Back to Top